Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial
- 24 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 26 (1), 71-75
- https://doi.org/10.1007/s10557-011-6358-9
Abstract
The action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby promoting vascular inflammation and increasing cardiovascular risk. Patients with acute coronary syndrome face a high risk of early, recurrent cardiovascular events that is associated with biomarkers of inflammation, including sPLA2. The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the hypothesis that varespladib methyl, an inhibitor of several sPLA2 isoforms with a causal role in atherosclerosis, reduces cardiovascular risk among patients with acute coronary syndromes. Up to 6,500 patients with acute coronary syndrome will be randomized to receive treatment with varespladib methyl 500 mg daily or placebo for 16 weeks, in addition to background treatment with atorvastatin and other evidence-based therapies. The primary efficacy parameter is the combination of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina with objective evidence of myocardial ischemia. Effects of varespladib methyl on lipid and inflammatory markers, in addition to safety and tolerability, will also be evaluated. sPLA2 inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome.Keywords
This publication has 23 references indexed in Scilit:
- The sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) TrialCirculation, 2010
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signalingThe FASEB Journal, 2010
- The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)Journal of Lipid Research, 2009
- The phospholipase A2 superfamily and its group numbering systemBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2006
- Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDLInternational Journal of Obesity, 2006
- Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary SyndromesJournal of the American College of Cardiology, 2005
- Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic RabbitsCirculation, 2005
- Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary interventionEuropean Heart Journal, 2003
- Role of Group II Secretory Phospholipase A2in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1999